{"id":1924,"date":"2025-04-10T13:08:04","date_gmt":"2025-04-10T13:08:04","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:08:04","modified_gmt":"2026-06-26T13:08:04","slug":"deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/","title":{"rendered":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101"},"content":{"rendered":"\n<p><strong>MONTR\u00c9AL, Canada, le 10 avril 2025 \u2013<\/strong>&nbsp;Find Therapeutics Inc., soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies auto-immunes, est fi\u00e8re d\u2019annoncer la nomination de deux nouveaux membres \u00e0 son conseil d\u2019administration : Dre Nancy Messier et Dr Thierry Abribat.<\/p>\n\n\n\n<p>\u00ab Nous sommes heureux d&#8217;accueillir la Dre Nancy Messier et le Dr Thierry Abribat au sein de notre conseil d&#8217;administration. Leur expertise compl\u00e9mentaire \u2013 dans la d\u00e9couverte de m\u00e9dicaments, le d\u00e9veloppement clinique et la strat\u00e9gie commerciale \u2013 est un atout pr\u00e9cieux pour Find alors que nous continuons \u00e0 faire progresser notre agent remy\u00e9linisant, FTX-101 \u00bb, a comment\u00e9 Paul F. Truex, pr\u00e9sident de Find, \u00ab Alors que FTX-101 approche de la fin des \u00e9tudes cliniques initiales chez l&#8217;homme, Nancy et Thierry seront inestimables pour nous aider \u00e0 guider nos prochaines \u00e9tapes. &nbsp;Le nouveau m\u00e9canisme de FTX-101 repr\u00e9sente une approche prometteuse pour diverses maladies auto-immunes o\u00f9 la r\u00e9paration et la reconstruction de la my\u00e9line pourraient \u00eatre un changement monumental pour les patients. &nbsp;Nous avons la chance de pouvoir compter sur leur expertise et nous nous r\u00e9jouissons de leurs contributions.<\/p>\n\n\n\n<p>En tant que Vice-pr\u00e9sidente, D\u00e9couverte de m\u00e9dicaments chez Feldan Therapeutics, la Dre Messier supervise la d\u00e9couverte de m\u00e9dicaments et le d\u00e9veloppement pr\u00e9clinique de th\u00e9rapies innovantes \u00e0 l&#8217;aide du Shuttle, une plateforme de livraison intracellulaire \u00e0 base de peptides. Ses travaux sur le traitement intral\u00e9sionnel du carcinome basocellulaire ont men\u00e9 \u00e0 un premier essai clinique chez l&#8217;humain \u00e0 l&#8217;automne 2024. La Dre Messier a obtenu un doctorat en microbiologie de l&#8217;Universit\u00e9 Laval \u00e0 la suite de ses travaux sur la r\u00e9sistance aux antibiotiques men\u00e9s au Centre de recherche en Infectiologie (CHUQ) \u00e0 Qu\u00e9bec. &nbsp;<\/p>\n\n\n\n<p>Dr Abribat est un dirigeant d&#8217;entreprises biotechnologiques et un entrepreneur en s\u00e9rie qui a cr\u00e9\u00e9, g\u00e9r\u00e9 et c\u00e9d\u00e9 trois soci\u00e9t\u00e9s de biotechnologie, fournissant des m\u00e9dicaments innovants aux patients, tout en offrant constamment des rendements positifs aux investisseurs : Aliz\u00e9 Pharma, acquise par Millendo Therapeutics (2017); Aliz\u00e9 Pharma 2, acquise par Jazz Pharmaceuticals (2016); et Amolyt Pharma, acquise par AstraZeneca (2024). Avant sa carri\u00e8re entrepreneuraile, il a occup\u00e9 plusieurs postes de direction avec des responsabilit\u00e9s croissantes dans le d\u00e9veloppement de m\u00e9dicaments, le d\u00e9veloppement des affaires et la gestion, \u00e0 titre de Chef de la direction scientifique chez Theratechnologies (TSX :TH, Montr\u00e9al, Canada) et de Chef de l&#8217;exploitation chez OPi SA, Pharmaceuticals for Rare Diseases &nbsp;(Lyon, France), jusqu&#8217;\u00e0 l&#8217;acquisition d&#8217;OPi par EUSA Pharma Inc en 2007. Le Dr Abribat est docteur en m\u00e9decine v\u00e9t\u00e9rinaire et titulaire d&#8217;un doctorat en neuroendocrinologie de l&#8217;Institut national polytechnique de Toulouse.<\/p>\n\n\n\n<p><strong>\u00c0 propos de FTX-101<\/strong><\/p>\n\n\n\n<p>Le compos\u00e9 principal de Find Therapeu cs, FTX-101, est un agent remy\u00e9linisant pionnier qui vise \u00e0 restaurer la vision des personnes souffrant de neuropathie op que chronique. FTX-101 est un pep de th\u00e9rapeu que qui cible le complexe des r\u00e9cepteurs de la plexine A1 et la neuropiline 1, pr\u00e9sent dans le cerveau et qui s&#8217;est av\u00e9r\u00e9 impliqu\u00e9 dans la migra on et la diff\u00e9rencia on des cellules pr\u00e9curseurs des oligodendrocytes en oligodendrocytes my\u00e9linisants. Des donn\u00e9es pr\u00e9cliniques probantes pour FTX-101 dans des mod\u00e8les d\u00e9my\u00e9linisants montrent une forte ac vit\u00e9 de r\u00e9para on de la my\u00e9line. &nbsp;<\/p>\n\n\n\n<p>\u00c0 propos de Find<\/p>\n\n\n\n<p>Find Therapeutics est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique qui se consacre au d\u00e9veloppement de th\u00e9rapies de nouvelle g\u00e9n\u00e9ration pour traiter les maladies autoimmunes inflammatoires. L&#8217;entreprise a \u00e9t\u00e9 lanc\u00e9e en 2020 et est soutenue par des investissements de CTI Life Sciences, adMare BioInnovations&nbsp;et Investissement Qu\u00e9bec, avec une licence exclusive de la SATT-Conectus et de l&#8217;Universit\u00e9 de Strasbourg sur la technologie et le savoir-faire connexe. Visitez www.findtherapeutics.com pour plus de d\u00e9tails sur Find Therapeutics.<\/p>\n\n\n\n<p><strong>Contact pour les investisseurs:&nbsp;<\/strong><br>investor@findtherapeutics.com<br>514-665-7322&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.findtherapeutics.com\/fr\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/\">Lire le communiqu\u00e9 original<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MONTR\u00c9AL, Canada, le 10 avril 2025 \u2013&nbsp;Find Therapeutics Inc., soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies auto-immunes, est fi\u00e8re d\u2019annoncer la nomination de deux nouveaux membres [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[110],"class_list":["post-1924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare\" \/>\n<meta property=\"og:description\" content=\"MONTR\u00c9AL, Canada, le 10 avril 2025 \u2013&nbsp;Find Therapeutics Inc., soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies auto-immunes, est fi\u00e8re d\u2019annoncer la nomination de deux nouveaux membres [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T13:08:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101\",\"datePublished\":\"2025-04-10T13:08:04+00:00\",\"dateModified\":\"2026-06-26T13:08:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/\"},\"wordCount\":686,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/\",\"name\":\"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"datePublished\":\"2025-04-10T13:08:04+00:00\",\"dateModified\":\"2026-06-26T13:08:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare","og_description":"MONTR\u00c9AL, Canada, le 10 avril 2025 \u2013&nbsp;Find Therapeutics Inc., soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies auto-immunes, est fi\u00e8re d\u2019annoncer la nomination de deux nouveaux membres [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/","og_site_name":"adMare","article_published_time":"2025-04-10T13:08:04+00:00","article_modified_time":"2026-06-26T13:08:04+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101","datePublished":"2025-04-10T13:08:04+00:00","dateModified":"2026-06-26T13:08:04+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/"},"wordCount":686,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/","name":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","datePublished":"2025-04-10T13:08:04+00:00","dateModified":"2026-06-26T13:08:04+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1924"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1924\/revisions"}],"predecessor-version":[{"id":1926,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1924\/revisions\/1926"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1925"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1924"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}